Immunorestoration of anergic cancer patients by azimexon.
Azimexon, a new synthetic immunoadjuvant, can act on delayed-type hypersensitivity (DTH) reactions. Seven of 11 anergic cancer patients have been immunorestored by a relatively low dosage of azimexon. The effect on the lymphocyte responsiveness, and particularly of a new T-lymphocyte mitogen (TPA), are described. The possible mechanisms of the anergy of the cancer patients and of the mode of action of azimexon are discussed.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology*; D007167:Immunotherapy; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D009369:Neoplasms / Q000276:immunology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D001388:Aziridines; D001389:Azirines; C016866:azimexon; D013755:Tetradecanoylphorbol Acetate